Purple Biotech (PPBT) has released an update.
Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreaking CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The novel CAPTN-3 technology utilizes a tri-specific antibody approach to activate both T cells and NK cells, targeting the 5T4 antigen found in various solid tumors associated with poor clinical outcomes. This innovative therapy aims to enhance anti-tumor efficacy by inducing a strong localized immune response within the tumor microenvironment.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
